Filana Therapeutics, Inc. (NasdaqCM: FLNA)
Health Care · Pharmaceuticals · US
$0.92
-3.81% today · -56.3% 1Y
Filana Therapeutics, Inc. (NasdaqCM: FLNA) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $46.42M and employs 19 people.
Over the last twelve months the share price has lost 56.3%, trading between 0.85 and 4.98.
Tweenvest scores Filana Therapeutics, Inc. across four factors: quality 26/100. Its strongest factor is quality.
FLNA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $46.42M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.88
- Dividend yield
- —
- Beta (5Y)
- -0.69
- 52-week high
- $4.98
- 52-week low
- $0.85
- Avg volume (3M)
- —
- Shares outstanding
- 48.31M
- Employees
- 19
- Next earnings
- —
About Filana Therapeutics, Inc.
Filana Therapeutics, Inc. is a company dedicated to pioneering new pharmaceutical products and diagnostic technologies. A key area of its research is focused on creating potential treatments for Alzheimer's disease, including the investigational compounds PTI-125 and PTI-125Dx. Established by Remi Barbier in May 1998, the firm maintains its principal office in Austin, Texas.
- ISIN
- US14817C1071
- Founded
- 1998
- Listed since
- Jul 14, 2000
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,189.41 | -3.59% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $270.00 | -1.15% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $153.10 | -2.14% |
| Roche Holding AGSWX: ROP | $371.62B | CHF368.30 | -1.47% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £122.34 | -1.94% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.30 | -0.95% |
Figures last refreshed Aug 18, 2026.